{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:52:30Z","timestamp":1791406350297,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain invasion (BI) was incorporated as a major criterion for grade 2 meningiomas in the 2016 WHO guidelines. However, its prognostic value remains controversial due to variability in surgical sampling and histopathologic interpretation, as well as BI may be the consequence of mechanical forces related more with the size of the tumor than the biologic presence of an innately more aggressive biologic lesion. Despite advances in molecular characterization of meningiomas, the relevance of BI as an independent prognostic indicator remains unresolved. We sought to determine whether BI alone, taken out of context of other parameters, particularly tumor size, truly represents a more aggressive standalone feature, by comparing time-to-progression (TTP) in atypical meningiomas classified as such due to BI alone versus other atypical meningiomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-institutional retrospective cohort study of patients with resected meningiomas from 2003 to 2023 was performed. Pathology reports were reviewed and tumors were re-graded using current WHO criteria. Only WHO Grade 2 patients were included in the study. Patients were then divided into two cohorts: The BIOB (Brain Invasion Otherwise Benign) group and \u201cother criteria\u201d (OC) group. Primary outcome was TTR and association of factors with TTR were assessed using Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      131 patients with a mean age of 59.2\u2009\u00b1\u200915.9 years were included. Median (IQR) preoperative tumor volume was 34.3 cm\n                      <jats:sup>3<\/jats:sup>\n                      (16-57.9). Gross total resection was achieved in 69 (53%) tumors. 18 patients (14%) had adjuvant radiation. BI was noted in 78 (60%) patients, 45 (34%) of which were classified as BIOB. Mean radiographic follow-up was 74\u2009\u00b1\u200956 months. Progression was noted in 40 (31%) patients at a mean of 40\u2009\u00b1\u200939 months post-resection. Progression occurred in 17.8% of BIOB patients (8\/45) and 37.2% of OC patients (32\/86). Baseline demographic, radiologic, and treatment characteristics did not differ significantly between BIOB and OC groups (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.3). On univariate Cox regression, TTR was associated with the BIOB group (Hazard Ratio [HR]\u2009=\u20090.44,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036), GTR (HR\u2009=\u20090.29,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and residual volume (HR\u2009=\u20091.04,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). On multivariable Cox regression, BIOB was associated with longer TTR (HR\u2009=\u20090.44,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041), when controlling for GTR and posterior fossa location.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Atypical meningiomas secondary to brain invasion alone were associated with significantly longer TTR than tumors with other Grade 2 criteria. This was especially robust for larger BI-only tumors. Further research is needed to delineate if brain invasion should truly be a standalone criterion for Grade 2 classification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05783-1","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:01:58Z","timestamp":1789110118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meningiomas classified as grade 2 due to brain invasion alone have better progression-free survival than other atypical meningiomas"],"prefix":"10.1007","volume":"179","author":[{"given":"Salem M.","family":"Tos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Kollia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Mantziaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios A.","family":"Maragkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson","family":"Brantley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Beatriz","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok R.","family":"Asthagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"Supplement6","key":"5783_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021. Neuro-Oncol 26(Supplement6):vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","journal-title":"Neuro-Oncol"},{"key":"5783_CR2","doi-asserted-by":"publisher","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncol Published online June 28, 2021:noab150. https:\/\/doi.org\/10.1093\/neuonc\/noab150","DOI":"10.1093\/neuonc\/noab150"},{"issue":"2","key":"5783_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm F, Aldape KD, Brastianos PK et al (2025) cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro-Oncol 27(2):319\u2013330. https:\/\/doi.org\/10.1093\/neuonc\/noae170","journal-title":"Neuro-Oncol"},{"issue":"6","key":"5783_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl) 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol (Berl)"},{"issue":"8","key":"5783_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"issue":"12","key":"5783_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/00000478-199712000-00008","volume":"21","author":"A Perry","year":"1997","unstructured":"Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21(12):1455\u20131465. https:\/\/doi.org\/10.1097\/00000478-199712000-00008","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5783_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-016-1598-1","volume":"132","author":"P Baumgarten","year":"2016","unstructured":"Baumgarten P, Gessler F, Schittenhelm J et al (2016) Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol (Berl) 132(3):479\u2013481. https:\/\/doi.org\/10.1007\/s00401-016-1598-1","journal-title":"Acta Neuropathol (Berl)"},{"issue":"5","key":"5783_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5414\/NP300750","volume":"33","author":"J Pizem","year":"2014","unstructured":"Pizem J, Velnar T, Prestor B, Mlakar J, Popovic M (2014) Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen. Clin Neuropathol 33(5):354\u2013363. https:\/\/doi.org\/10.5414\/NP300750","journal-title":"Clin Neuropathol"},{"issue":"2","key":"5783_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10014-020-00390-y","volume":"38","author":"S Nakasu","year":"2021","unstructured":"Nakasu S, Nakasu Y (2021) Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis. Brain Tumor Pathol 38(2):81\u201395. https:\/\/doi.org\/10.1007\/s10014-020-00390-y","journal-title":"Brain Tumor Pathol"},{"key":"5783_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.wneu.2016.06.055","volume":"93","author":"DC Spille","year":"2016","unstructured":"Spille DC, He\u00df K, Sauerland C et al (2016) Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis. World Neurosurg 93:346\u2013354. https:\/\/doi.org\/10.1016\/j.wneu.2016.06.055","journal-title":"World Neurosurg"},{"issue":"9596","key":"5783_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"1","key":"5783_CR12","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1093\/neuros\/nyaa348","volume":"88","author":"ME Garcia-Segura","year":"2020","unstructured":"Garcia-Segura ME, Erickson AW, Jairath R, Munoz DG, Das S (2020) Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. Neurosurgery 88(1):E42\u2013E48. https:\/\/doi.org\/10.1093\/neuros\/nyaa348","journal-title":"Neurosurgery"},{"issue":"3","key":"5783_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11060-019-03312-x","volume":"145","author":"A Biczok","year":"2019","unstructured":"Biczok A, Jungk C, Egensperger R et al (2019) Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. J Neurooncol 145(3):469\u2013477. https:\/\/doi.org\/10.1007\/s11060-019-03312-x","journal-title":"J Neurooncol"},{"issue":"3","key":"5783_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3171\/2022.6.JNS221162","volume":"138","author":"JI Traylor","year":"2023","unstructured":"Traylor JI, Plitt AR, Hicks WH, Mian TM, Mickey BE, Barnett SL (2023) Evaluating risk of recurrence in patients with meningioma. J Neurosurg 138(3):621\u2013628. https:\/\/doi.org\/10.3171\/2022.6.JNS221162","journal-title":"J Neurosurg"},{"issue":"2","key":"5783_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10014-021-00419-w","volume":"39","author":"MS Kim","year":"2022","unstructured":"Kim MS, Chun SW, Dho YS et al (2022) Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis. Brain Tumor Pathol 39(2):99\u2013110. https:\/\/doi.org\/10.1007\/s10014-021-00419-w","journal-title":"Brain Tumor Pathol"},{"issue":"6","key":"5783_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/nan.12700","volume":"47","author":"R Banan","year":"2021","unstructured":"Banan R, Abbetmeier-Basse M, Hong B et al (2021) The prognostic significance of clinicopathological features in meningiomas: Microscopic brain invasion can predict patient outcome in otherwise benign meningiomas. Neuropathol Appl Neurobiol 47(6):724\u2013735. https:\/\/doi.org\/10.1111\/nan.12700","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"5783_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3171\/2023.2.JNS222751","volume":"139","author":"HY Li","year":"2023","unstructured":"Li HY, Ying YZ, Zheng D et al (2023) Is brain invasion sufficient as a stand-alone criterion for grading atypical meningioma? J Neurosurg 139(4):953\u2013964. https:\/\/doi.org\/10.3171\/2023.2.JNS222751","journal-title":"J Neurosurg"},{"issue":"1","key":"5783_CR18","doi-asserted-by":"publisher","first-page":"vdag167","DOI":"10.1093\/noajnl\/vdag167","volume":"8","author":"L Zhang","year":"2026","unstructured":"Zhang L, Lou L, Fu W, Wu L, Fu X, Zhang S, Wang X (2026) Brain invasion as a diagnostic histological feature of atypical meningiomas: Not a standalone diagnostic criterion. Neurooncol Adv 8(1):vdag167. https:\/\/doi.org\/10.1093\/noajnl\/vdag167","journal-title":"Neurooncol Adv"},{"issue":"3","key":"5783_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11060-021-03892-7","volume":"155","author":"F Behling","year":"2021","unstructured":"Behling F, Fodi C, Wang S et al (2021) Increased proliferation is associated with CNS invasion in meningiomas. J Neurooncol 155(3):247\u2013254. https:\/\/doi.org\/10.1007\/s11060-021-03892-7","journal-title":"J Neurooncol"},{"key":"5783_CR20","doi-asserted-by":"publisher","first-page":"1189606","DOI":"10.3389\/fnins.2023.1189606","volume":"17","author":"K Gousias","year":"2023","unstructured":"Gousias K, Trakolis L, Simon M (2023) Meningiomas with CNS invasion. Front Neurosci 17:1189606. https:\/\/doi.org\/10.3389\/fnins.2023.1189606","journal-title":"Front Neurosci"},{"issue":"5","key":"5783_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.pathol.2020.10.024","volume":"53","author":"P Dal Col","year":"2021","unstructured":"Dal Col P, Garaix T, Massard A et al (2021) Meningioma sampling: how much is enough for the accurate grading of atypical meningiomas? Pathol (Phila) 53(5):602\u2013607. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.024","journal-title":"Pathol (Phila)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05783-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:03:26Z","timestamp":1791403406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5783"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05783-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of Virginia Institutional Review Board for Health Sciences Research (IRB-HSR).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the University of Virginia Institutional Review Board for Health Sciences Research (IRB-HSR). The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"79"}}